Mirena 52 MG systems
Ended Awarded
- Contract number
- SPE2DR26FBYLK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,315
Award facts
- Contract value 100% obligated
- $5,314.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $5,314.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Mirena 52 mg contraceptive systems. The contract, awarded on November 4, 2025, with an ultimate completion date of November 26, 2025, utilizes firm fixed-price pricing with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group was selected as the awardee based on its established capabilities as a critical supplier within the federal pharmaceutical supply chain and its demonstrated performance on numerous prior delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, valued at $499,999,999 with a ceiling through December 31, 2036, authorizes the company to supply a comprehensive range of pharmaceutical products and medical consumables to support Department of Defense military healthcare operations globally. The company's single-award contract position within the PPV-G GEN V program demonstrates DLA's confidence in DMS Pharmaceutical Group's ability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FBYLK?
SPE2DR26FBYLK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DR26FBYLK worth?
The government has obligated $5,315 on SPE2DR26FBYLK.
Is contract SPE2DR26FBYLK an order under another contract?
Yes. SPE2DR26FBYLK is a delivery order under SPE2DR25D9103, an indefinite delivery contract.
Was contract SPE2DR26FBYLK competed?
The extent of competition for SPE2DR26FBYLK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award